Parkinson's Cure Journey

Metabolic drug repurposing

The lane

Status
Narrowed. Several attempts failed; work continues in a smaller group or with a different drug.
Verdict
Exenatide Phase 3 (now under a Lancet expression of concern), NLY01, pioglitazone and simvastatin failed; lixisenatide Phase 2 was positive.
Family
Body
Landmarks
13 in this lane, 1 more tagged with it. Advanced 2 · Open 4 · Pending 1 · Superseded 1 · Dead end 5

The verdict and status come from the project's branches.yaml and use research wording.

Landmarks in this lane

13 landmarks drawn in this lane, oldest first. Select a column heading to sort.
Type 2 diabetes raises Parkinson's risk2011–2018DiscoveryConfirmed and built on––19 Oct 20263
Exenatide pilot2013Trial in peopleReplaced by a newer approach––19 Oct 20262
Pioglitazone (FS-ZONE)2015Trial in peopleDid not work221019 Oct 20263
The GLP-1 idea: can diabetes drugs slow Parkinson's?2017–2025DiscoveryStill being studied––19 Oct 20262
Semaglutide Phase 2 trials (Oslo, MOST-ABLE)2019–2026Trial in peopleMixed or early results2–22 Oct 20263
PT320 slow-release exenatide2020–2021Trial in peopleMixed or early results29922 Oct 20264
Stockholm exenatide trial2020–2025Trial in peopleDid not work25919 Oct 20264
Diabetes and Parkinson's: Mendelian randomisation2021DiscoveryConfirmed and built on––20 Oct 20261
Simvastatin (PD STAT)2022Trial in peopleDid not work–23519 Oct 20262
NLY01 Phase 22023Trial in peopleDid not work225519 Oct 20265
MOST-ABLE: oral semaglutide (Osaka)2023–2027Trial in peopleResult due Mar 202729919 Oct 20264
Lixisenatide Phase 2 (LixiPark)2024Trial in peopleMixed or early results215619 Oct 20264
Exenatide Phase 3 (Exenatide-PD3)2025Trial in peopleDid not work319419 Oct 20265

Also tagged with this lane

1 landmarks drawn in another lane but tagged with this one. Select a column heading to sort.
Microglia can turn astrocytes toxic2017–2018DiscoveryStill being studied––19 Oct 20262

Built on work from

Led to work in

See this lane on the map · All lanes